| Code | CSB-RA001670MB2HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is developed as a research-grade biosimilar to Crebankitug, targeting the interleukin-7 receptor (IL7R, also known as CD127). IL7R is a type I transmembrane protein that forms part of the heterodimeric receptor complex for interleukin-7, a critical cytokine essential for T-cell and B-cell development, homeostasis, and survival. The receptor plays a pivotal role in lymphocyte maturation and maintaining peripheral T-cell populations. Dysregulation of IL7R signaling has been implicated in various autoimmune conditions, including multiple sclerosis, inflammatory bowel disease, and rheumatoid arthritis, as well as in certain hematological malignancies and primary immunodeficiencies.
Crebankitug is a therapeutic monoclonal antibody designed to modulate IL7R activity, currently under investigation for treating autoimmune disorders. This biosimilar provides researchers with a valuable tool for investigating IL7R-mediated immune responses, studying lymphocyte biology, exploring therapeutic mechanisms in autoimmune disease models, and evaluating IL7R as a potential biomarker. It serves as an important reagent for advancing understanding of immune system regulation and developing novel immunotherapeutic strategies.
There are currently no reviews for this product.